Deschiens M A, Conard J, Horellou M H, Ameri A, Preter M, Chedru F, Samama M M, Bousser M G
Service de Neurologie Hôpital Saint-Antoine, Paris, France.
Stroke. 1996 Oct;27(10):1724-30. doi: 10.1161/01.str.27.10.1724.
Cerebral venous thrombosis (CVT) is an infrequent condition with a large variety of causes. However, in 20% to 35% of cases, no cause is found. We studied coagulation parameters, including activated protein C resistance associated with factor V gene mutation (factor V Leiden) and anticardiolipin antibodies, in a large series of patients with CVT with or without identified cause or risk factor.
Forty patients (30 women and 10 men) aged 19 to 71 years (mean age, 36.2 years) with CVT diagnosed by angiography and/or MRI were studied 1 to 18 years after thrombosis. No known cause was found in 10 idiopathic cases. Coagulation studies included the following tests: fibrinogen, antithrombin, protein C, protein S, plasminogen, anticardiolipin antibodies, activated protein C resistance, and factor V Leiden.
Six cases of thrombophilia (15%) were found: 1 protein C deficiency, 1 protein S deficiency, and 4 activated protein C resistance with heterozygous factor V Leiden mutation (10%). Only 1 case (protein S deficiency) was found in the group of 10 patients with idiopathic CVT. In the other 5, there was another cause or risk factor. Three patients (8%) had increased anticardiolipin antibodies: 1 with systemic lupus and 2 with primary antiphospholipid syndrome; 2 of these 3 patients also had factor V Leiden mutation.
Although present in a number of CVT cases, acquired (anticardiolipin) or congenital varieties of thrombophilia (factor V Leiden being the most frequent) are almost invariably associated with other predisposing factors. This suggests that (1) these abnormalities should be looked for in patients with CVT, whether a cause is found or not, and (2) their presence should not deter the search for other potential causes. The detection of such abnormalities has major practical consequences on the long-term management of patients to prevent further thrombotic episodes.
脑静脉血栓形成(CVT)是一种病因多样的罕见病症。然而,在20%至35%的病例中,病因不明。我们研究了一系列有或无明确病因或危险因素的CVT患者的凝血参数,包括与因子V基因突变(因子V莱顿突变)相关的活化蛋白C抵抗和抗心磷脂抗体。
对40例经血管造影和/或MRI诊断为CVT的患者进行了研究,这些患者年龄在19至71岁之间(平均年龄36.2岁),血栓形成后1至18年。10例特发性病例未发现已知病因。凝血研究包括以下检测:纤维蛋白原、抗凝血酶、蛋白C、蛋白S、纤溶酶原、抗心磷脂抗体、活化蛋白C抵抗和因子V莱顿突变。
发现6例血栓形成倾向(15%):1例蛋白C缺乏,1例蛋白S缺乏,4例因杂合子因子V莱顿突变导致的活化蛋白C抵抗(10%)。在10例特发性CVT患者组中仅发现1例(蛋白S缺乏)。在其他5例中,存在其他病因或危险因素。3例患者(8%)抗心磷脂抗体升高:1例患有系统性红斑狼疮,2例患有原发性抗磷脂综合征;这3例患者中有2例也存在因子V莱顿突变。
尽管在许多CVT病例中存在获得性(抗心磷脂)或先天性血栓形成倾向(因子V莱顿突变最为常见),但几乎总是与其他易感因素相关。这表明:(1)无论是否找到病因,都应在CVT患者中寻找这些异常;(2)它们的存在不应妨碍寻找其他潜在病因。检测到这些异常对患者的长期管理以预防进一步血栓形成事件具有重大实际意义。